Shenkang® Entacapone/Levodopa/Carbidopa Tablets (II) Launches Nationally Online via AliHealth to Address Unmet Needs in Parkinson’s Disease Treatment

December 22,Qilu Pharmaceutical Group Co., Ltd.Under its umbrellaEntacapone and Levodopa Tablets (Ⅱ) (Trade name: Shenkean®)Launched on AliHealth.The drugApplicable for treatment with levodopaAdult patients with Parkinson's disease who have failed to be controlled by dopa decarboxylase (DDC) inhibitor therapy or experience "wearing-off" motor fluctuations。

According to "China Parkinson's Disease Diagnosis and TreatmentGuidelines (Fourth Edition)" (2020) shows，ChinaThe prevalence rate in people over 65 years old is about 1.7%.。Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease, with clinical features including motor symptoms such as bradykinesia, tremor, and rigidity, as well as non-motor symptoms.。ChinaHas become"The largest country with Parkinson's disease,"The total number of patients has exceeded3 Million。

As the disease progresses,A significant proportion of patients receiving long-term levodopa treatment will experience“End-of-dose Phenomenon”，That is, the duration of drug efficacy is shortened, and motor symptoms re-aggravate before the next dose, seriously affecting daily living abilities and quality of life.

Shen Ke'an® By integrating three components—levodopa, carbidopa, and entacapone—into a single combination tablet.。In the "Guidelines for the Treatment of Parkinson's Disease in China,"It is recommended that this type of compound levodopa preparation be used as the first-choice treatment for patients with motor fluctuations., while Entacapone and Carbidopa can improveLevodopaBrain entry level, extend its half-life, while reducing the production of dopamine peripherally, thereby effectively alleviating peripheral adverse reactions.In addition,Combining three ingredients into one tablet also simplifies the medication regimen.`, which helps improve patients' long-term treatment adherence.`

Shen Ke'an®TheThe successful approval marks an important advancement for Qilu Pharmaceutical in the field of central nervous system treatment, and it also represents a significant milestone for Qilu Pharmaceutical.The #rd Approved for Marketing This Year22 New Products. As a large-scale comprehensive modern pharmaceutical enterprise in China, Qilu Pharmaceutical has established including"National Engineering Research Center for Drug Formulations" and other national-level R&D platforms。Product treatment covers tumors, infections, cardiovascular and cerebrovascular diseases, psychiatric and neurological systems, and ophthalmology., Autoimmune, Diabetes, etc.Multiple fields.

AliHealthAs"New Specialty Drug Launch Platform", this time as Shen Ke An®'s first channel, providing rapid access to target patientsPath, relying on professional medical science popularization, pharmacist services, and a convenient medicine purchasing and delivery network., helping Parkinson's disease patients gain access to more accessible disease management solutions.

At the same time, AliHealth actively responds to the advocacy of "China Parkinson's Disease Treatment Guidelines""The Whole-process Management" Concept. This guideline emphasizes that the treatment of Parkinson's disease needs to dynamically adjust strategies according to different stages of the disease, with particular attention to the prevention and management of motor complications in the early stage of the disease.In response to the current widespread challenges such as the difficulty of seeking medical treatment in different places and the inconvenience of regular follow-up visits, AliHealth has built an online management loop for patients that covers diagnosis, treatment, and long-term follow-ups through digital tools like online follow-up consultations, medication reminders, and symptom tracking. This effort helps enhance the continuity of standardized treatment and improve patients' quality of life.